REAL-WORLD OUTCOMES IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH FIRST-LINE CHEMOTHERAPY IN THE UNITED STATES: RESULTS FROM A RETROSPECTIVE ANALYSIS

OBJECTIVES: This retrospective study examined therapeutic outcomes to first-line (1L) chemotherapy in patients with distant metastatic Merkel cell carcinoma (mMCC). MCC is a rare, aggressive skin cancer associated with poor prognosis in patients with metastatic disease. Advanced MCC is typically tre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Value in health 2017-05, Vol.20 (5), p.A95
Hauptverfasser: Cowey, CL, Mahnke, L, Espirito, J, Helwig, C, Oksen, D, Bharmal, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page A95
container_title Value in health
container_volume 20
creator Cowey, CL
Mahnke, L
Espirito, J
Helwig, C
Oksen, D
Bharmal, M
description OBJECTIVES: This retrospective study examined therapeutic outcomes to first-line (1L) chemotherapy in patients with distant metastatic Merkel cell carcinoma (mMCC). MCC is a rare, aggressive skin cancer associated with poor prognosis in patients with metastatic disease. Advanced MCC is typically treated with che­motherapy, but there is no approved standard-of-care treatment. METHODS: Data were obtained from the US Oncology Network/McKesson Specialty Health electro­nic health record database and medical charts. Qualifying patients were adults with distant mMCC who had received 1L chemotherapy between 11/2004 and 9/ 2014 with follow-up until 6/2015. Patients who received treatment with any drug targeting T-cell coregulatory proteins were excluded, among other eligibility criteria. Objective response rate (ORR) to 1L chemotherapy was assessed using RECIST vl.l as a guide, and duration of response (DOR), time to treatment discontinuation (TTD), progression-free survival (PFS), and overall survival (OS) were estimated using Kaplan-Meier methodology. The primary analysis popula­tion was patients with immunocompetent status. RESULTS: Of 686 patients identified to have MCC, 67 qualified for analysis (76% immunocompetent/24% immunocompromised). In immunocompetent patients (n=51) at start of 1L chemotherapy, median age was 78 years, 84% were male, 49% had an ECOG performance status of 1, and 69% were diagnosed initially with stage I-III disease. The most common 1L regimen was carboplatin + etoposide (63%). ORR was 29.4% (95% CI, 17.5-43.8), median DOR was 6.7 mos (95% CI, 1.2-10.5; interquartile range, 2.3-12.1), median TTD was 2.4 mos (95% CI, 2.2-2.9), median PFS was 4.6 mos (95% CI, 2.8-7.7), and median OS was 10.5 mos (95% CI, 7.2-15.2). Results in the overall population were consistent with those in the immunocompetent popula­tion. CONCLUSIONS: In patients with distant mMCC treated with 1L chemother­apy, responses were of limited duration. The median survival was less than 1 year, highlighting the need for novel therapies.
doi_str_mv 10.1016/j.jval.2017.05.005
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2097661124</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2097661124</sourcerecordid><originalsourceid>FETCH-proquest_journals_20976611243</originalsourceid><addsrcrecordid>eNqNjUtOwzAQhi0EEuVxAVYjsU6w86TsLHeqWDh2ZE-ouqq6KIuootBQjsQ5cQQHYDPzz8ynbxi7EzwVXFQPQzp8bfdpxkWd8jLlvDxjM1FmRVLUeX4eM58_JjkX5SW7GseBc17lWTlj3x6lSVbOmwW4npRrMYC20EnSaCnASlMDLZIMFFcqRv-MBhSaWKRX2rpWAkUN4eKXXmofKDHaIqgGW0cNetmtJ22M0Fs9oZMPwxN4DL2Jj5betSDjSN6FDhXpFwRppVkHHW7Yxet2P-5u__o1u18iqSZ5Px4-TrvxczMcTse3eNpkfF5XlRBZkf-P-gE8vlZV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2097661124</pqid></control><display><type>article</type><title>REAL-WORLD OUTCOMES IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH FIRST-LINE CHEMOTHERAPY IN THE UNITED STATES: RESULTS FROM A RETROSPECTIVE ANALYSIS</title><source>ScienceDirect Freedom Collection (Elsevier)</source><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>Free E-Journal (出版社公開部分のみ)</source><creator>Cowey, CL ; Mahnke, L ; Espirito, J ; Helwig, C ; Oksen, D ; Bharmal, M</creator><creatorcontrib>Cowey, CL ; Mahnke, L ; Espirito, J ; Helwig, C ; Oksen, D ; Bharmal, M</creatorcontrib><description>OBJECTIVES: This retrospective study examined therapeutic outcomes to first-line (1L) chemotherapy in patients with distant metastatic Merkel cell carcinoma (mMCC). MCC is a rare, aggressive skin cancer associated with poor prognosis in patients with metastatic disease. Advanced MCC is typically treated with che­motherapy, but there is no approved standard-of-care treatment. METHODS: Data were obtained from the US Oncology Network/McKesson Specialty Health electro­nic health record database and medical charts. Qualifying patients were adults with distant mMCC who had received 1L chemotherapy between 11/2004 and 9/ 2014 with follow-up until 6/2015. Patients who received treatment with any drug targeting T-cell coregulatory proteins were excluded, among other eligibility criteria. Objective response rate (ORR) to 1L chemotherapy was assessed using RECIST vl.l as a guide, and duration of response (DOR), time to treatment discontinuation (TTD), progression-free survival (PFS), and overall survival (OS) were estimated using Kaplan-Meier methodology. The primary analysis popula­tion was patients with immunocompetent status. RESULTS: Of 686 patients identified to have MCC, 67 qualified for analysis (76% immunocompetent/24% immunocompromised). In immunocompetent patients (n=51) at start of 1L chemotherapy, median age was 78 years, 84% were male, 49% had an ECOG performance status of 1, and 69% were diagnosed initially with stage I-III disease. The most common 1L regimen was carboplatin + etoposide (63%). ORR was 29.4% (95% CI, 17.5-43.8), median DOR was 6.7 mos (95% CI, 1.2-10.5; interquartile range, 2.3-12.1), median TTD was 2.4 mos (95% CI, 2.2-2.9), median PFS was 4.6 mos (95% CI, 2.8-7.7), and median OS was 10.5 mos (95% CI, 7.2-15.2). Results in the overall population were consistent with those in the immunocompetent popula­tion. CONCLUSIONS: In patients with distant mMCC treated with 1L chemother­apy, responses were of limited duration. The median survival was less than 1 year, highlighting the need for novel therapies.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1016/j.jval.2017.05.005</identifier><language>eng</language><publisher>Lawrenceville: Elsevier Science Ltd</publisher><subject>Carboplatin ; Chemotherapy ; Discontinued ; Distant ; Drug abuse ; Electronic medical records ; Etoposide ; Lymphocytes T ; Medical prognosis ; Metastases ; Metastasis ; Oncology ; Patients ; Proteins ; Response rates ; Skin cancer</subject><ispartof>Value in health, 2017-05, Vol.20 (5), p.A95</ispartof><rights>Copyright Elsevier Science Ltd. May 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,30999</link.rule.ids></links><search><creatorcontrib>Cowey, CL</creatorcontrib><creatorcontrib>Mahnke, L</creatorcontrib><creatorcontrib>Espirito, J</creatorcontrib><creatorcontrib>Helwig, C</creatorcontrib><creatorcontrib>Oksen, D</creatorcontrib><creatorcontrib>Bharmal, M</creatorcontrib><title>REAL-WORLD OUTCOMES IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH FIRST-LINE CHEMOTHERAPY IN THE UNITED STATES: RESULTS FROM A RETROSPECTIVE ANALYSIS</title><title>Value in health</title><description>OBJECTIVES: This retrospective study examined therapeutic outcomes to first-line (1L) chemotherapy in patients with distant metastatic Merkel cell carcinoma (mMCC). MCC is a rare, aggressive skin cancer associated with poor prognosis in patients with metastatic disease. Advanced MCC is typically treated with che­motherapy, but there is no approved standard-of-care treatment. METHODS: Data were obtained from the US Oncology Network/McKesson Specialty Health electro­nic health record database and medical charts. Qualifying patients were adults with distant mMCC who had received 1L chemotherapy between 11/2004 and 9/ 2014 with follow-up until 6/2015. Patients who received treatment with any drug targeting T-cell coregulatory proteins were excluded, among other eligibility criteria. Objective response rate (ORR) to 1L chemotherapy was assessed using RECIST vl.l as a guide, and duration of response (DOR), time to treatment discontinuation (TTD), progression-free survival (PFS), and overall survival (OS) were estimated using Kaplan-Meier methodology. The primary analysis popula­tion was patients with immunocompetent status. RESULTS: Of 686 patients identified to have MCC, 67 qualified for analysis (76% immunocompetent/24% immunocompromised). In immunocompetent patients (n=51) at start of 1L chemotherapy, median age was 78 years, 84% were male, 49% had an ECOG performance status of 1, and 69% were diagnosed initially with stage I-III disease. The most common 1L regimen was carboplatin + etoposide (63%). ORR was 29.4% (95% CI, 17.5-43.8), median DOR was 6.7 mos (95% CI, 1.2-10.5; interquartile range, 2.3-12.1), median TTD was 2.4 mos (95% CI, 2.2-2.9), median PFS was 4.6 mos (95% CI, 2.8-7.7), and median OS was 10.5 mos (95% CI, 7.2-15.2). Results in the overall population were consistent with those in the immunocompetent popula­tion. CONCLUSIONS: In patients with distant mMCC treated with 1L chemother­apy, responses were of limited duration. The median survival was less than 1 year, highlighting the need for novel therapies.</description><subject>Carboplatin</subject><subject>Chemotherapy</subject><subject>Discontinued</subject><subject>Distant</subject><subject>Drug abuse</subject><subject>Electronic medical records</subject><subject>Etoposide</subject><subject>Lymphocytes T</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Patients</subject><subject>Proteins</subject><subject>Response rates</subject><subject>Skin cancer</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNqNjUtOwzAQhi0EEuVxAVYjsU6w86TsLHeqWDh2ZE-ouqq6KIuootBQjsQ5cQQHYDPzz8ynbxi7EzwVXFQPQzp8bfdpxkWd8jLlvDxjM1FmRVLUeX4eM58_JjkX5SW7GseBc17lWTlj3x6lSVbOmwW4npRrMYC20EnSaCnASlMDLZIMFFcqRv-MBhSaWKRX2rpWAkUN4eKXXmofKDHaIqgGW0cNetmtJ22M0Fs9oZMPwxN4DL2Jj5betSDjSN6FDhXpFwRppVkHHW7Yxet2P-5u__o1u18iqSZ5Px4-TrvxczMcTse3eNpkfF5XlRBZkf-P-gE8vlZV</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Cowey, CL</creator><creator>Mahnke, L</creator><creator>Espirito, J</creator><creator>Helwig, C</creator><creator>Oksen, D</creator><creator>Bharmal, M</creator><general>Elsevier Science Ltd</general><scope>7QJ</scope></search><sort><creationdate>20170501</creationdate><title>REAL-WORLD OUTCOMES IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH FIRST-LINE CHEMOTHERAPY IN THE UNITED STATES: RESULTS FROM A RETROSPECTIVE ANALYSIS</title><author>Cowey, CL ; Mahnke, L ; Espirito, J ; Helwig, C ; Oksen, D ; Bharmal, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_20976611243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Carboplatin</topic><topic>Chemotherapy</topic><topic>Discontinued</topic><topic>Distant</topic><topic>Drug abuse</topic><topic>Electronic medical records</topic><topic>Etoposide</topic><topic>Lymphocytes T</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Patients</topic><topic>Proteins</topic><topic>Response rates</topic><topic>Skin cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cowey, CL</creatorcontrib><creatorcontrib>Mahnke, L</creatorcontrib><creatorcontrib>Espirito, J</creatorcontrib><creatorcontrib>Helwig, C</creatorcontrib><creatorcontrib>Oksen, D</creatorcontrib><creatorcontrib>Bharmal, M</creatorcontrib><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cowey, CL</au><au>Mahnke, L</au><au>Espirito, J</au><au>Helwig, C</au><au>Oksen, D</au><au>Bharmal, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>REAL-WORLD OUTCOMES IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH FIRST-LINE CHEMOTHERAPY IN THE UNITED STATES: RESULTS FROM A RETROSPECTIVE ANALYSIS</atitle><jtitle>Value in health</jtitle><date>2017-05-01</date><risdate>2017</risdate><volume>20</volume><issue>5</issue><spage>A95</spage><pages>A95-</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>OBJECTIVES: This retrospective study examined therapeutic outcomes to first-line (1L) chemotherapy in patients with distant metastatic Merkel cell carcinoma (mMCC). MCC is a rare, aggressive skin cancer associated with poor prognosis in patients with metastatic disease. Advanced MCC is typically treated with che­motherapy, but there is no approved standard-of-care treatment. METHODS: Data were obtained from the US Oncology Network/McKesson Specialty Health electro­nic health record database and medical charts. Qualifying patients were adults with distant mMCC who had received 1L chemotherapy between 11/2004 and 9/ 2014 with follow-up until 6/2015. Patients who received treatment with any drug targeting T-cell coregulatory proteins were excluded, among other eligibility criteria. Objective response rate (ORR) to 1L chemotherapy was assessed using RECIST vl.l as a guide, and duration of response (DOR), time to treatment discontinuation (TTD), progression-free survival (PFS), and overall survival (OS) were estimated using Kaplan-Meier methodology. The primary analysis popula­tion was patients with immunocompetent status. RESULTS: Of 686 patients identified to have MCC, 67 qualified for analysis (76% immunocompetent/24% immunocompromised). In immunocompetent patients (n=51) at start of 1L chemotherapy, median age was 78 years, 84% were male, 49% had an ECOG performance status of 1, and 69% were diagnosed initially with stage I-III disease. The most common 1L regimen was carboplatin + etoposide (63%). ORR was 29.4% (95% CI, 17.5-43.8), median DOR was 6.7 mos (95% CI, 1.2-10.5; interquartile range, 2.3-12.1), median TTD was 2.4 mos (95% CI, 2.2-2.9), median PFS was 4.6 mos (95% CI, 2.8-7.7), and median OS was 10.5 mos (95% CI, 7.2-15.2). Results in the overall population were consistent with those in the immunocompetent popula­tion. CONCLUSIONS: In patients with distant mMCC treated with 1L chemother­apy, responses were of limited duration. The median survival was less than 1 year, highlighting the need for novel therapies.</abstract><cop>Lawrenceville</cop><pub>Elsevier Science Ltd</pub><doi>10.1016/j.jval.2017.05.005</doi></addata></record>
fulltext fulltext
identifier ISSN: 1098-3015
ispartof Value in health, 2017-05, Vol.20 (5), p.A95
issn 1098-3015
1524-4733
language eng
recordid cdi_proquest_journals_2097661124
source ScienceDirect Freedom Collection (Elsevier); Applied Social Sciences Index & Abstracts (ASSIA); Free E-Journal (出版社公開部分のみ)
subjects Carboplatin
Chemotherapy
Discontinued
Distant
Drug abuse
Electronic medical records
Etoposide
Lymphocytes T
Medical prognosis
Metastases
Metastasis
Oncology
Patients
Proteins
Response rates
Skin cancer
title REAL-WORLD OUTCOMES IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH FIRST-LINE CHEMOTHERAPY IN THE UNITED STATES: RESULTS FROM A RETROSPECTIVE ANALYSIS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A33%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=REAL-WORLD%20OUTCOMES%20IN%20PATIENTS%20WITH%20METASTATIC%20MERKEL%20CELL%20CARCINOMA%20TREATED%20WITH%20FIRST-LINE%20CHEMOTHERAPY%20IN%20THE%20UNITED%20STATES:%20RESULTS%20FROM%20A%20RETROSPECTIVE%20ANALYSIS&rft.jtitle=Value%20in%20health&rft.au=Cowey,%20CL&rft.date=2017-05-01&rft.volume=20&rft.issue=5&rft.spage=A95&rft.pages=A95-&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1016/j.jval.2017.05.005&rft_dat=%3Cproquest%3E2097661124%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2097661124&rft_id=info:pmid/&rfr_iscdi=true